Anup Kumar Kasi Loknath Kumar
Hematology & Oncology · Westwood, KSNPI 1841429750
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,615 of the $30,958 with a category attached, or 60.1%. 6 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 47.7% of the total.
Across 55 payments — averaging $562.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$15K
- Novocure Inc.$9K
- Corcept Therapeutics$5K
- Seagen Inc.$2K
- GSK$67
- Genentech, Inc.$53
Across 1,290 payments — averaging $11,834 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$5.7M
- Astellas US Technologies$4.5M
- Astellas Pharma Inc$3.1M
- Astellas Pharma Global Development$655K
- Gilead$596K
- Pfizer$245K
- plus $411K from 5 others
What the payments were for
- Consulting fees$6,67022%
- Speaking & faculty fees$18,61560%
- Travel & lodging$4,05813%
- Food & beverage$1,4955%
- Education$1200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 18 | $14,778 |
| Novocure Inc. | 22 | $9,119 |
| Corcept Therapeutics | 12 | $5,191 |
| Seagen Inc. | 1 | $1,750 |
| GSK | 1 | $67 |
| Genentech, Inc. | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,958 in reported general payments places this provider in the 80th percentile of 97 hematology & oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 58 | $221,823 |
| XermeloTelotristat Etiprate | 12 | $120,711 |
| ZenpepLipase/Protease/Amylase | 17 | $57,960 |
| EliquisApixaban | 47 | $35,719 |
| XareltoRivaroxaban | 24 | $26,300 |
| Imatinib Mesylate | 47 | $7,254 |
| Potassium Chloride | 53 | $1,518 |
| Prochlorperazine Maleate | 52 | $755 |
| Dexamethasone | 62 | $745 |
| Ondansetron Hcl | 67 | $614 |
| LoperamideLoperamide Hcl | 21 | $543 |
| Ondansetron OdtOndansetron | 20 | $522 |
| Duloxetine Hcl | 15 | $422 |
| Gabapentin | 30 | $344 |
| Oxycodone Hcl | 12 | $307 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Westwood
- Priyanka SharmaWestwood$135K
- Gary DoolittleWestwood$102K
- Sunil AbhyankarWestwood$78K
- Leyla ShuneWestwood$56K
- Anthony SungWestwood$49K
- Prakash NeupaneWestwood$26K
- Muhammad Umair MushtaqWestwood$21K
- Jesus Gonzalez LugoWestwood$4K
- Qamar KhanWestwood$1K
- Tahani AtiehWestwood$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.